Cemiplimab in the treatment of cutaneous squamous cell carcinoma

Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of cutaneous squamous cell carcinoma (CSCC). Cemiplimab, a human IgG4 monoclonal antibody to the programmed death-1 (PD-1) receptor, has shown impressive response rates and durable disease control in patients with advanced CSCC, alongside a manageable safety profile. More recently, cemiplimab has demonstrated promising efficacy in both the adjuvant and neoadjuvant settings, with impressive improvements in disease-free survival and pathological response rates. This review provides a comprehensive overview of the current role of cemiplimab in the management of CSCC, highlighting key clinical trial data and real-world evidence on its efficacy and safety.